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Introduction: Lung cancer is the highest cause of mortality among 
tumor pathologies worldwide. There are no validated techniques for an 
early detection of pulmonary cancer lesions other than low-dose heli-
cal computed tomography scan. Unfortunately, this method has some 
negative effects. Recent studies have laid the basis for development of 
exosomes-based techniques to screen/diagnose lung cancers. As the 
isolation of circulating exosomes is a minimally invasive procedure, 
this technique opens new possibilities for diagnostic applications.
Methods: We used a first set of 30 plasma samples from as many 
patients, including 10 patients affected by lung adenocarcinomas, 
10 with lung granulomas, and 10 healthy smokers matched for 
age and sex as negative controls. Wide-range microRNAs analysis 
(742 microRNAs) was performed by quantitative real time poly-
merase chain reaction. Data were compared on the basis of lesion 
characteristics, using WEKA software for statistics and modeling. 
Subsequently, selected microRNAs were evaluated on an indepen-
dent larger group of samples (105 specimens: 50 lung adenocarcino-
mas, 30 lung granulomas, and 25 healthy smokers).
Results: This analysis led to the selection of four microRNAs to 
perform a screening test (miR-378a, miR-379, miR-139-5p, and 
miR-200b-5p), useful to divide population into two groups: nodule 
(lung adenocarcinomas + carcinomas) and non-nodule (healthy for-
mer smokers). Six microRNAs (miR-151a-5p, miR-30a-3p, miR-
200b-5p, miR-629, miR-100, and miR-154-3p) were selected for a 
second test on the nodule population to discriminate between lung 
adenocarcinoma and granuloma.
Conclusions: The screening test showed 97.5% sensitivity, 72.0% 
specificity, and area under the curve receiver operating characteristic 
of 90.8%. The diagnostic test had 96.0% sensitivity, 60.0% speci-
ficity, and area under the curve receiver operating characteristic of 
76.0%. Further evaluation is needed to confirm the predictive power 
of these models on larger cohorts of samples.
Key Words: Exosome, Screening test, Diagnostic test, Lung adeno-
carcinoma, microRNA.
(J Thorac Oncol. 2013;8: 1156-1162)
Lung cancer is the leading cause of cancer-related deaths worldwide. Most lung lesions are diagnosed at advanced 
stages with an overall 5-year survival rate of 15%.1 With 
the exception of the recently published U.S. National Lung 
Screening Trial2 there are no validated population-based 
screening procedures. Furthermore, there are no serum/plasma 
biomarkers to determine whether a low-dose helical computer-
ized tomogram should be performed in high-risk individuals.
Exosomes are microvesicles specialized in transporting 
different types of molecules currently seen as a short-/long-
range communication system.3 microRNAs are small mol-
ecules with capacity of posttranscriptional regulation, and a 
single microRNA has the abilities to bind with several mRNAs 
through a suppressor complex and block an entire biological 
pathway. Numerous proteins may be found within exosomes 
but RNA, with a strong percentage of microRNAs,4–6 seems to 
predominate in these structures.
Several articles have demonstrated the importance of 
circulating exosomes and microRNAs regarding: lung cancer 
detection,6,7 discrimination among histotypes,8 development 
and prognosis,9 and early detection.10 Furthermore, it has been 
suggested that cells can produce specific microRNAs that 
respond to stimuli or messages from adjacent cells.11
Tumor cells are a perfect illustration of this paradigm 
because they produce exosomes containing microRNAs com-
pletely different from those present in normal cells from which 
neoplastic cells originated.12 Cancer cells use the exosomes 
for many purposes, including the control of adjacent cells 
without inducing any mutation or confusion in the immune 
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system, by facilitating the migration of metastases over long 
distances, evading detection by the targeted stromal cells in a 
Trojan-horse–like process.13
The aim of the present study was to develop two plasma-
based tests, one for screening and one for diagnosis of lung 
adenocarcinoma. Plasma-based diagnostics could fit, by their 
nature, in a prevention policy based on periodic checks.
MATERIALS AND METHODS
Plasma Samples
Training Set
Thirty frozen plasma samples were selected for the 
study group from the NYU plasma bank and grouped into the 
following three categories: 10 lung adenocarcinomas, 10 lung 
granulomas, and 10 healthy former smokers. Samples were 
matched for age, sex, and smoking history. A total of 500 μl of 
plasma was taken from each sample. This group was analyzed 
on the microRNA Ready-to-Use PCR, Human panel I+II, 
V2.M (Exiqon, Vedbæk, Denmark).
Validation Set
A subsequent quantitative real time polymerase chain 
reaction (RT-PCR) validation group that was matched for age, 
sex, and smoking history, consisted of 50 lung adenocarcinomas, 
30 lung granulomas, and 25 healthy former smokers. For this 
second analysis group was used 250 μl of plasma each sample.
Selection Criteria
To select the training set samples we decided to use 
restrictive selection criteria regarding the patients: age ranging 
from 40 to 80 years, being smokers at the time of sampling, 
low racial variability, equal mix of both sexes, and early-stage 
nodule (Ia or Ib) with regard to lung adenocarcinomas and 
granulomas.
Selection criteria for the validation set were less restric-
tive. We maintained the same age range (40–80 years), being 
smokers, having tumors, lung granulomas in early stage, and 
no allowance was made for sex and race variability (Table 1).
Exosome Precipitation and microRNA  
Extraction Protocol
First, 126 µl of ExoQuick exosome precipitation solu-
tion (System Biosciences, Mountain View, CA) was added to 
the 500 µl of stored plasma to precipitate exosome pellet, as 
described by manufacturer. This exosome pellet was lysed in 
300 µl of RNeasy Lysis Buffer RLT (Qiagen, Milano, Italy), 
and then a Trizol (Life Technologies, Grand Island, NY) RNA 
extraction was performed with addition of MS2 phage RNA 
carrier (Roche, Basel, Switzerland); 800 μl of Trizol + 1.25 μl 
MS2 RNA carrier; ratio of Trizol to chloroform was 4:1. All 
concentrations were halved for the subsequent RNA extrac-
tion of validation group.
TABLE 1.  Overview of Population Characteristics
Variable
Adenocarcinomas
(n = 50)
Granulomas
(n = 30)
Healthy
(n = 25) p
Study set (n = 10) (n = 10) (n = 10)
  Age, mean ± SD 66.1 ± 14.0 64.8 ± 13.7 65.6 ± 7.4 0.971a
  Sex, n (%) 0.861b
  Male  3 (30.0)  3 (30.0)  4 (40.0)
  Female  7 (70.0)  7 (70.0)  6 (60.0)
  Smoking habit, n (%) 0.024b
  Yes  5 (50.0)  5 (50.0) 10 (100.0)
  No  5 (50.0)  5 (50.0) —
Nodule size, mean ± SD 1.42 ± 0.24 1.34 ± 0.56 — 0.683c
Validation set
  Age, mean ± SD 70.5 ± 9.2 65.6 ± 9.5 66.7 ± 8.8 0.050a
  Sex, n (%) 0.126b
  Male 25 (50.0) 11 (36.7) 16 (64.0)
  Female 25 (50.0) 19 (63.3)  9 (36.0)
  Smoke habits, n (%) 0.151b
  Yes 41 (82.0) 16 (53.3)  3 (12.0)
  No  9 (18.0) 11 (36.7) 22 (88.0)
  Unknown —  3 (10.0) —
Nodule size, mean ± SD 1.49 ± 0.45 1.34 ± 0.56 — 0.192c
aOne-way ANOVA test.
bχ2 test.
cStudent’s t test for unpaired data.
ANOVA, analysis of variance.
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cDNA Synthesis, microRNAs Plates, 
and Quantitative RT-PCR
Seven microliters of Trizol-extracted RNA, in 20 µl 
of total volume, were subjected to reverse transcription with 
miRCURY LNA Universal cDNA synthesis kit (Exiqon), 
incubated for 60 minutes at 42°C followed by enzyme heat 
inactivation for 5 minutes at 95°C. Wide-range microRNAs 
analysis was performed using microRNA Ready-to-Use PCR, 
Human panel I+II, V2.M (Exiqon) according to manufactur-
er’s protocol.
Quantitative RT-PCR was carried out in total volume 
of 10-µl reaction mixture (384-well format) using miRCURY 
LNA Universal RT microRNA PCR, SYBR Green mas-
ter mix (Exiqon) according to the manufacturer’s protocol. 
Amplification was performed as follows: 95°C for 10 minutes, 
40 cycles of 95°C for 10 seconds, and 60°C for 10 seconds, 
ramp rate 100% under standard condition.
microRNAs expression was determined using the ABI 
7900HT and was quantified using SDS software version 2.4 
(Life Technologies, Grand Island, NY), setting a threshold of 
1.0 and a manual baseline from one to 13 cycles. The valida-
tion cohort was analyzed in triplicate.
Evaluation of Appropriate Housekeeping  
microRNA
Because of the absence of reference genes in the plasma 
samples, it was critical to choose an appropriate housekeeping 
microRNA. Ten samples were chosen at random in the train-
ing set (3 lung granulomas, 3 lung adenocarcinomas, and 4 
healthy). Let-7a, mir-20a, mir-221a,12 mir-16,14 and let-7b were 
tested by RT-PCR (every sample in duplicates). glyceraldehyde 
3-phosphate dehydrogenase was also examined. Resulting data 
were analyzed using Normfinder software Version 0.953.15
Evaluation of the Stability of microRNAs in  
Plasma Samples
To validate whether our plasma samples storage 
resulted in stable levels of the microRNAs, we also evalu-
ated microRNA concentrations in plasma over time and after 
freeze–thaw. A single blood sample was selected randomly 
and the plasma was divided into several aliquots from which 
RNA extractions were performed. These aliquots included 
fresh plasma and frozen plasma for five different periods: 24 
hours, 48 hours, 1 week, 1 month, and 2 months. The follow-
ing microRNAs were tested in these aliquots using quanti-
tative RT-PCR: let-7a, mir-20a, and mir-221. One spiked-in 
synthetic control (reagent content in cDNA synthesis kit; 
Exiqon) was added artificially to the cDNA synthesis in a 
known amount to evaluate the reaction quality.
Wide-Range microRNAs Profiling
The two Exiqon plates (microRNA Ready-to-Use PCR, 
Human Panel I + II, V2.M; Exiqon) allowed quantitative 
RT-PCR of 742 human microRNAs, six reference genes, and 
relative internal controls/calibrators. To avoid any kind of 
contamination, the plates were dispensed using the Biomek 
3000 laboratory automation workstation (Beckman Coulter, 
Brea, CA).
Statistical Method of microRNA Selection
The quantitative variables were summarized as mean ± 
SE. The qualitative variables were summarized as frequency 
and percentage. Statistical analysis was performed using para-
metric tests because the distribution of the variables was nor-
mal, calculated with Shapiro-Wilk test.
The first step of the analysis was conducted on the 
training set to develop a potential screening test, samples 
were regrouped into two categories to compare differences in 
microRNAs: nodules (10 lung adenocarcinomas + 10 granu-
lomas) versus nonnodules (10 healthy former smokers). To 
develop a diagnostic test, aimed to describe the malignancy 
of nodules group samples, only the 10 lung adenocarcinomas 
(cancers group) were compared with the 10 lung granulomas 
(granulomas group).
One-way analysis of variance or Student’s t test for 
unpaired, when appropriate, was performed to evaluate statis-
tically significant differences of quantitative variables among 
groups; χ2 test was applied on qualitative variables.
CfsSubsetEval (class attributes) function of WEKA 
software version 3.6.4 (University of Waikato, Hamilton, New 
Zealand)16 was used to select the more informative microR-
NAs for the discrimination between lung adenocarcinomas, 
lung granulomas, and healthy former smokers groups in the 
training set. This method assesses the predictive ability of 
each attribute, as well as the degree of redundancy among 
each microRNA. It prefers attributes that are highly corre-
lated within each class, but that have low intercorrelation. The 
choice of attributes was performed using 10-fold cross-valida-
tion, and selection of the 14 best attributes was based on their 
being selected at least 50% of the time.17
To evaluate the statistically significant differences 
between nodules versus nonnodules and granulomas versus 
cancers in the selected microRNAs of the entire validation 
cohort (105 samples: 50 lung adenocarcinomas, 30 lung 
granulomas, and 25 healthy former smokers), a Student’s t 
test for unpaired data with Benjamini-Hochberg correction 
for multiple comparisons was used; false-discovery rate was 
set to 0.05.
Statistical Modeling and Validation
Starting from the previously selected microRNAs a 
stepwise logistic regression analysis (class SimpleLogistic in 
the WEKA software package) was conducted, on training set, 
to choose a best model to classify nodules versus nonnodules. 
Analysis was performed with 20-fold cross-validation, 500 
max boosting interactions, 50 heuristic stop. The same pro-
cedure was conducted to choose the best model to classify 
granuloma versus cancer. Screening models were applied on 
the entire validation cohort of 105 samples.
Diagnostic models were applied on lung adenocarci-
noma and lung granuloma samples taken from the validation 
set, 80 samples. Alpha (α) values were evaluated for each 
sample. To quantify the goodness of screening and diagnos-
tic models, the sensitivity, specificity, positive and negative 
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predictive values, and receiver operating characteristic curve 
analysis were evaluated separately.
RESULTS
Before starting with microRNA profiling, some critical 
issues were addressed, including: selection of an appropriate 
housekeeping microRNA to normalize RT-PCR results and 
assessment of stability of exosomes in frozen archival plasma 
samples. The main aim of this study was to select the lowest 
number of microRNAs useful to create a strong screening and 
diagnostic model.
Housekeeping microRNA Selection
According to previously published articles,12,14 and the 
Exiqon RT-PCR manual, five microRNAs (Let-7a, mir-20a, 
mir-221a, mir-16, and let-7b) and GAPDH were selected to be 
evaluated as possible housekeeping microRNA on a random 
cohort of 10 samples. Normfinder software was used to give a 
numerical evaluation of stability with relative SEs.
Let-7a expression showed the lowest output value and 
error, proving to be the best housekeeping microRNA among 
those analyzed (Fig. 1 supplementary data, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A468); this in accordance 
with the findings of Chen et al.12 GAPDH expression, instead, 
was found in only two of 10 samples (data not shown).
microRNA (and Exosome) Stability 
in Frozen Plasma Samples
To assess the stability of microRNAs extracted from 
plasma conserved for different period of time at −80°C, vari-
ous aliquots of the same sample (fresh plasma and 5 frozen 
plasma aliquots, stored for: 24 hours, 48 hours, 1 week, 1 
month, and 2 months after preparation) were subjected to 
RNA extraction and RT-PCR using mir-20a, mir-221a, and 
Let-7a primers. The raw Ct are showed in Figure 1, there were 
no detectable oscillations in the total concentration of exam-
ined microRNAs.
Spiked-in RNA was used to evaluate the quality of the 
whole PCR reaction, it showed a low statistical deviation from 
arithmetic mean (<0.25 Ct) evidence of good quality PCR 
reactions, which allow us to directly compare different sam-
ples of raw Ct.
This evidence confirmed that exosomes remained unal-
tered in plasma when properly stored at −80°C.17
microRNAs Profiling and Selection 
of Interesting microRNAs
Wide-range microRNA analysis has shown that 278 
microRNAs were expressed in all three studied groups. On 
these 278 microRNAs, statistical analysis was performed 
via WEKA software (CfsSubsetEval analysis) as described 
in Materials and Methods section. The 14 best microRNAs 
FIGURE 1. A and B, Exosome stability in time. 
We analyzed exosome stability in frozen samples 
using raw Ct of mir-20a, mir-221, and Let-7a. 
Graphs show reverse-transcriptase polymerase 
chain reaction of resulting raw Ct of the same 
plasma sample, divided in several aliquots and 
RNA extracted from fresh plasma aliquot and 
frozen plasma aliquots at 24 hours, 48 hours, 
1 week, 1 month, and 2 months. Graph (A) 
shows raw Cts of the various aliquots and the 
duplicate tests divided by microRNAs. Graph (B) 
compares microRNA trends in time. There is no 
detectable oscillation of microRNA raw Cts from 
fresh aliquot to the one frozen for 2 months.
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(characterized by the highest CfsSubsetEval value) were 
selected to be further evaluated in the validation cohort.
miR-502-5p, miR-376a-5p, miR-1974, miR-378a, miR-
379, miR-151a-5p, miR-139-5p, miR-200b-5p, miR-190b, 
miR-30a-3p, miR-629, miR-17, miR-100, and miR-154-3p 
were found to be the best microRNAs by CfsSubsetEval anal-
ysis; the results ranged between a higher value of 100% and a 
lower value of 50% (Fig. 2 supplementary data, Supplemental 
Digital Content 2, http://links.lww.com/JTO/A469). The 
quantitative RT-PCR data obtained on the validation series 
were used to double check these 14 microRNAs by fold-
changes technique and t tests. The acquired p values were 
for nodules versus nonnodules and for granulomas versus 
adenocarcinomas.
Concerning lung granulomas expression levels, only 
three to 14 microRNAs were slightly down-regulated (miR-
139-5p, miR-30a-3p, miR-378a) with less than −0.5 expres-
sion level value. Ten microRNAs were found up-regulated: 
miR-502-5p, miR-1974, miR-17, miR-100, and miR-154-3p 
were slightly up-regulated (≤0.5); miR-376a-5p, miR-378a, 
miR-379, miR-139-5p, miR-30a-3p, and miR-629 were moder-
ately up-regulated (expression levels value between 0.5 and 1); 
miR-200b-5p and miR-190b were highly up-regulated (>1).
miR-151a-5p Has Shown no Expression Levels Regarding 
Lung Granulomas.
Regarding lung adenocarcinomas there was no down-
regulation, all 14 microRNAs were up-regulated: miR-151a-5p, 
miR-1974, and miR-139-5p were slightly up-regulated (≤0.5); 
miR-376a-5p, miR-378a, miR-379, miR-30a-3p, and miR-
154-3p were moderately up-regulated (expression levels value 
between 0.5 and 1); miR-200b-5p, miR-190b, miR-502-5p, 
miR-629, miR-17, and miR-100 were highly up-regulated 
(>1). Expression levels are shown in Figure 2.
p Values, obtained by testing the validation cohort 
ΔΔCts, were used to evaluate whether data were statistically 
significant and useful for the construction of the screening test, 
the diagnostic test, or both. Box-whiskers graphs of selected 
microRNAs are available in supplementary data Figure 3 
(Supplemental Digital Content 3 [http://links.lww.com/JTO/
A470] and 4 [http://links.lww.com/JTO/A471]).
Student’s t test nodule versus nonnodule confirmed that 
three to 14 microRNAs were useful for the statistic modeling 
of lung cancer screening test: miR-151a-5p, miR-139-5p, and 
miR-1974; five other microRNAs, miR-379, miR-200b-5p, 
miR-502-5p, miR-378a, and miR-100 could be considered sig-
nificant for p value less than 0.05. Student’s t test lung granu-
lomas versus lung adenocarcinoma has shown the importance 
of eight microRNAs for the development of the diagnostic test: 
miR-17, miR-30a-3p, miR-378a, miR-151a-5p, miR-502-5p, 
miR-154-3p, miR-100, miR-139-5p, in the same way that miR-
200b-5p and miR-629 could be considered significant for p 
value less than 0.05 (Table 1 supplementary data, Supplemental 
Digital Content 5, http://links.lww.com/JTO/A472).
microRNA Evaluation and Test Modeling Results
The models were created with WEKA software as 
described in Materials and Methods section. Starting from 
the previously described 14 microRNAs, modeling software 
attempted to use the smallest number of microRNAs to describe 
the data set. Regarding the screening test, selected microR-
NAs are: miR-378a, miR-379, miR-139-5p, and miR-200-5p. 
Concerning the diagnostic test, selected microRNAs are: miR-
151a-5p, miR-30a-3p, miR-200b-5p, miR-629, miR-100, and 
miR-154-3p. The specific results for both typologies of test are 
reported below in Table 2; Figures 3 and 4 show receiver operat-
ing characteristic curves of the two tests.
FIGURE 2.  Overview of microRNA expression levels. After 
data set normalization, the log10 of 2
(−ΔΔCt) was taken each 
microRNA. The graph shows expression level value of each 
microRNA, one for lung adenocarcinomas from healthy 
controls (reported as cancer bars in the graph) and another 
for lung granulomas from healthy controls (reported as 
granuloma bars in the graph). Concerning lung granuloma 
expression levels, three to 14 microRNAs showed slight 
down-regulation, 10 microRNAs were found up-regulated. 
miR-151a-5p showed no expression levels compared with 
normal donors. All 14 microRNAs resulted in up-regulation in 
lung adenocarcinoma expression levels.
TABLE 2.  Overview of Test Characteristics
Test Sensitivity Specificity Positive Predictive Value Negative Predictive Value AUC ROC
Screening test, % 97.5 72 92 90 90.8
Screening algorithm α = 0.86 + (miR378a) (−0.3) + (miR379) (0.19) + (miR-139-5p) (0.37) + (miR-200b-5p) (−0.17)
Diagnostic test, % 96 60 80 90  76
Diagnostic algorithm α = −0.89 + (miR-151a-5p) (−0.15) + (miR-200b-5p) (0.07) + (miR-30a-3p) (0.05) + 
+(miR629) (−0.17) + (miR100) (0.04) + (miR-154-3p) (−0.05)
Shows the tests characteristics: sensibility, specificity, positive predictive value, negative predictive value, and AUC ROC. It also shows the tests algorithms.
AUC ROC, area under the curve receiver operating characteristic.
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DISCUSSION
This study was designed for a very specific purpose, the 
development of two tests useful in a two-step policy of diag-
nosis for lung adenocarcinoma. Prevention and periodic tests 
have revealed that mortality can be reduced for colon and rec-
tum, breast, and uterine cervix cancers.18
Currently, lung cancer has the highest mortality rate and 
is the second most common cancer in both men (after prostate 
cancer) and women (after breast cancer). About 28% of all 
cancer deaths can be ascribed to this pathology; about 15% of 
all new cancers are non–small-cell lung cancer or small-cell 
lung cancer.18–22
Although low-dose spiral computed tomography (CT or 
helical CT) has shown some promise in detecting early lung 
cancers in heavy smokers and former smokers,2,23 we are still 
far from getting results comparable with those of breast cancer.
This technique is useful in detecting small abnormali-
ties in the lung, but it is known to have some downsides and 
impacts on the patient overall health.23,24
Circulating exosomes, and their microRNA content, 
have opened a new field for molecular diagnostics. microR-
NAs could suppress specific protein synthesis and entire bio-
logical pathways in exosome-targeted cells.25
Exosome-based diagnostic techniques have the potential 
for having high reproducibility and require only a blood sam-
pling. It is our opinion that any alteration in the healthy status 
could lead to a change of microRNAs pattern in the blood-
stream. A high-throughput study, as the one presented in this 
article, could be a step to decode the exo/miR-code by which 
cells exchange messages and influence each other’s biological 
cycle, without affecting the general structure of their genomes.
Correlations between microRNAs deregulated in tissues 
compared with bloodstream have rarely been observed. Plasma 
samples could be useful independently of tissue specimens.12
In this study we moved from a wide-range analysis 
of 746 microRNAs to a narrow selection of 14 microRNAs 
known to have different functions. miR-200b-5p was used as 
a biomarker to assess the recurrence of small-cell lung tumors 
after surgical resection.26 miR-100, miR-378a, and miR-629 
primarily regulate the expression of PPP3CA and FZD, two 
important oncogenes in colorectal cancer and basal cell car-
cinoma, having at the same time a lower affinity with genes 
of the map-kinase cascade.27–29 Some of the microRNAs are 
important in the long-term potentiation pathway (mir-30a, 
miR-139-5p). The mir-30a is involved in metastasis and cel-
lular invasion, targeting the gene Snai1 and inhibiting the epi-
thelial/mesenchymal transition.30 miR-139-5p is involved in 
kidney and colorectal cancer and has been used for molecu-
lar diagnosis of these forms.31,32 miR-151a-5p acts mainly 
on the response of the map-kinase cascade, important in cell 
migration and invasion,33 it also varies in response to ionizing 
radiation.34 Mir-154 has privileged target genes in UBE2D2, 
UBE2D3, and CUL2, which are involved in ubiquitin-medi-
ated proteolysis.35 The miR-379 has a strong affinity with the 
gene HLCS involved in the metabolism of biotin, and genes 
involving regulation of cell adhesion, also important in patient 
response to drugs and their relative resistance.36,37
This study must be confirmed with a larger data set. We 
do not yet know the affects of sex, age, and cancer treatment 
on microRNAs levels in plasma. Our data suggest that exo-
somes analysis in plasma samples are better suited to screen 
a high-risk population than discriminate between malignant 
and nonmalignant lesions. Currently, with the exception of 
CT scan, there is no screening technique for lung cancer that 
can compete with other techniques implemented for different 
types of cancer. CT scan showed a tendency to overestimate 
FIGURE 4.  Diagnosis model ROC curve. ROC plot for 
diagnostic model microRNA set. The diagnostic model 
distinguishes between lung adenocarcinoma and granuloma 
patients with an area under the curve = 0.760 (p < 0.001). 
ROC, receiver operating characteristic.
FIGURE 3.  Screening model ROC curve. ROC plot for 
screening model microRNA set. The screening model distin-
guishes between control subjects and patients with any kind 
of nodules (lung adenocarcinomas and granulomas) with 
an area under the curve = 0.908 (p < 0.001). ROC, receiver 
operating characteristic.
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significantly the number of positives. A total of 96.4% of 
the positive screening results in the low-dose CT group, in 
a recent U.S. National screening trial,2 were false positive. 
Having also a number of negative effects on the patient, the CT 
scan is a test not repeatable in the short term. Molecular tests 
can be repeated a virtually infinite number of times, without 
any damage to patients. This pilot study showed a specificity 
of 72%; false-positive rate is therefore significantly reduced 
when compared with that of the CT scan.
The importance of the biological role of exosomes is 
growing exponentially in recent years of research. Further 
studies are needed to fully understand this new way of cell to 
cell communication. We strongly believe in the opportunity to 
choose exosomes as screening–diagnostic tools.
REFERENCES
 1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact 
of eliminating socioeconomic and racial disparities on premature cancer 
deaths. CA Cancer J Clin 2011;61:212–236.
 2. The National Lung Screening Trial Research Team. Reduced lung-cancer 
mortality with low-dose computed tomographic screening. N Engl J Med 
2011;365:395–409.
 3. Zomer A, Vendrig T, Hopmans ES, van Eijndhoven M, Middeldorp JM, 
Pegtel DM. Exosomes: fit to deliver small RNA. Commun Integr Biol 
2010;3:447–450.
 4. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as sta-
ble blood-based markers for cancer detection. Proc Natl Acad Sci U S A 
2008;105:10513–10518.
 5. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: 
a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 
2009;9:703–711.
 6. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med 
2009;60:167–179.
 7. Shen J, Todd NW, Zhang H, et al. Plasma microRNAs as potential bio-
markers for non-small-cell lung cancer. Lab Invest 2011;91:579–587.
 8. Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-
miR-205 expression distinguishes squamous from nonsquamous non-
small-cell lung carcinoma. J Clin Oncol 2009;27:2030–2037.
 9. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and 
plasma predict development and prognosis of CT detected lung cancer. 
Proc Natl Acad Sci USA 2011;108(9):3713–3718.
 10. Zheng D, Haddadin S, Wang Y, et al. Plasma microRNAs as novel 
biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 
2011;4:575–586.
 11. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. 
Exosome-mediated transfer of mRNAs and microRNAs is a novel mecha-
nism of genetic exchange between cells. Nat Cell Biol 2007;9:654–659.
 12. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a 
novel class of biomarkers for diagnosis of cancer and other diseases. Cell 
Res 2008;18:997–1006.
 13. Yang C, Robbins PD. The roles of tumor-derived exosomes in cancer 
pathogenesis. Clin Dev Immunol 2011;2011:842849.
 14. Juan W, Wen G, Cheng-Jun Z, et al. Identification of plasma microRNA-21 
as a biomarker for early detection and chemosensitivity of non-small cell 
lung cancer. Chin J Cancer 2011;30(6):407–414.
 15. Jensen J, Ørntoft T. Normalization of real-time quantitative RT-PCR data: 
a model based variance estimation approach to identify genes suited for 
normalization—applied to bladder- and colon-cancer data-sets. Cancer 
Research 2004;(64):5245–5250.
 16. Witten IH, Frank E. Data Mining: Practical Machine Learning Tools and 
Techniques, 2nd Ed. San Francisco, CA: Morgan Kaufmann, 2005.
 17. Lodes MJ, Caraballo M, Suciu D, et al. Detection of cancer with 
Serum microRNAs on an Oligonucleotide Microarray. PLoS One 
2009;4(7):e6229.
 18. National Cancer Institute. Statistical tools and data (Cancer.gov web site). 
May, 2011. Available at: http://www.cancer.gov/statistics. Accessed may 
5, 2011.
 19. Heisey R, Clemons M, Granek L, et al. Health care strategies to promote 
earlier presentation of symptomatic breast cancer: perspectives of women 
and family physicians. Curr Oncol 2011;18:e227–e237.
 20. Majek O, Danes J, Skovajsova M, et al. Breast cancer screening in 
the Czech Republic: time trends in performance indicators during 
the first seven years of the organised programme. BMC Public Health 
2011;11:288.
 21. Arolfo S, Teggia PM, Nano M. Gastrointestinal stromal tumors: thirty 
years experience of an institution. World J Gastroenterol 2011;17: 
1836–1839.
 22. Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH. 
Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung 
Cancer 2009;10:42–46.
 23. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. 
Computed tomography screening and lung cancer outcomes. JAMA 
2007;297:953–961.
 24. Pastorino U. Lung cancer screening. Br J Cancer 2010;102:1681–1686.
 25. Davalos V, Esteller M. MicroRNAs and cancer epigenetics: a macrorevo-
lution. Curr Opin Oncol 2010;22:35–45.
 26. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of 
microRNA expression profiles that may predict recurrence of localized 
stage I non-small cell lung cancer after surgical resection. Cancer Res 
2010;70:36–45.
 27. Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A, Yakhini Z. 
Novel rank-based statistical methods reveal microRNAs with differential 
expression in multiple cancer types. PLoS One 2009;4:e8003.
 28. Gao W, Shen H, Liu L, Xu J, Xu J, Shu Y. MiR-21 overexpression in 
human primary squamous cell lung carcinoma is associated with poor 
patient prognosis. J Cancer Res Clin Oncol 2011;137:557–566.
 29. Eichner LJ, Perry MC, Dufour CR, et al. miR-378(*) mediates metabolic 
shift in breast cancer cells via the PGC-1β/ERRγ transcriptional pathway. 
Cell Metab 2010;12:352–361.
 30. Kumarswamy R, Mudduluru G, Ceppi P, et al. MicroRNA-30a inhibits 
epithelial-to-mesenchymal transition by targeting Snai1 and is downregu-
lated in non-small cell lung cancer. Int J Cancer 2012;130:2044–2053.
 31. Fridman E, Dotan Z, Barshack I, et al. Accurate molecular classi-
fication of renal tumors using microRNA expression. J Mol Diagn 
2010;12:687–696.
 32. Chang KH, Miller N, Kheirelseid EA, et al. MicroRNA signature 
analysis in colorectal cancer: identification of expression profiles in 
stage II tumors associated with aggressive disease. Int J Colorectal Dis 
2011;26:1415–1422.
 33. Ding J, Huang S, Wu S, et al. Gain of miR-151 on chromosome 8q24.3 
facilitates tumour cell migration and spreading through downregulating 
RhoGDIA. Nat Cell Biol 2010;12:390–399.
 34. Niemoeller OM, Niyazi M, Corradini S, et al. MicroRNA expression 
profiles in human cancer cells after ionizing radiation. Radiat Oncol 
2011;6:29.
 35. Wang W, Peng B, Wang D, et al. Human tumor microRNA signatures 
derived from large-scale oligonucleotide microarray datasets. Int J 
Cancer 2011;129:1624–1634.
 36. Haenisch S, Laechelt S, Bruckmueller H, et al. Down-regulation of 
ATP-binding cassette C2 protein expression in HepG2 cells after 
rifampicin treatment is mediated by microRNA-379. Mol Pharmacol 
2011;80:314–320.
 37. Guo L, Liu Y, Bai Y, Sun Y, Xiao F, Guo Y. Gene expression profiling of 
drug-resistant small cell lung cancer cells by combining microRNA and 
cDNA expression analysis. Eur J Cancer 2010;46:1692–1702.
